GUERBET : Financial agenda for 2025

Financial agenda for 2025Villepinte, 31 October 2024:Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications calendar 2024 ANNUAL REVENUE February 06, 2025,after trading2024 ANNUAL RESULTS March 27, 2025, after trading2025 1 stQUARTER REVENUE April 24, 2025,after tradingANNUAL SHAREHOLDERS' MEETING May 23, 2025 2025 2 ndQUARTER...

Villepinte, 31/10/2024 (informazione.it - comunicati stampa - salute e benessere)

Financial agenda for 2025

Villepinte, 31 October 2024 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023.

Contacts:

Guerbet      
Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / jerome.estampes@guerbet.com  
Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / christine.allard@guerbet.com

Seitosei.Actifin                                                                                       
Marianne Py, Financial Communication + 33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33 1 56 88 11 19 / jennifer.jullia@seitosei-actifin.com

Attachment